Company Profile
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Latest News
KOC agrees $16bn pipeline deal with Blackstone, Brookfield, KKR
Meliá fully withdraws from Cuba amid economic crisis – report
Man Group PLC : Form 8.3 - AMG Critical Materials N.V
EU approves Saica’s acquisition of Thimm plants in four countries
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.csl.com |
| Audit Risk | 7 |
| Board Risk | 4 |
| Overall Risk | 5 |
| Market Cap | 55.74B |
| Trailing P/E | 13.18 |
| Forward P/E | 12.77 |
| Dividend Rate | 4.26 |
| Dividend Yield | 3.73% |
| Trailing Annual Div. Rate | 2.92 |
| Trailing Annual Div. Yield | 2.56% |
| Trailing EPS | 8.83 |
| Forward EPS | 9.11 |
| Book Value | 55.47 |
| Price-to-Book | 2.1 |
| Enterprise-to-Revenue | 4.34 |
| Enterprise-to-EBITDA | 13.82 |
| Ex-Dividend Date | 03/10/2026 |
| Earnings Date | |
| Earnings Call Date |